Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02173808 · ClinicalTrials.gov registry record · Phase 1

A Phase I Study to Evaluate the PK and PD of a Single Injection of Levonorgestrel Butanoate for Female Contraception

A Phase 1 study of Contraceptive Usage, sponsored by Premier Research.

Completed
Registry status
Phase 1
Development phase
16
Enrollment target
1
Study location

NCT02173808 is a Phase 1 study of Contraceptive Usage that has completed, run by Premier Research. The registered enrollment target is 16 participants, below the 627-participant average among 11 other Contraceptive Usage trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02173808, a Phase 1 study of Contraceptive Usage, has completed, sponsored by Premier Research.

COMPLETED
Registry status
Phase 1
Development phase
16 participants
Enrollment target
1
Study location

Study Summary

To evaluate the levonorgestrel (LNG) pharmacokinetic (PK) profile following injection of a single 20 mg dose of levonorgestrel butanoate (LB).

Conditions Studied

Interventions

  • BIOLOGICAL levonorgestrel butanoate

Study Locations (1)

Oregon

  • Oregon Health & Science University - Portland

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2011-05
Est. Completion 2012-06
Phase Phase 1

Sponsor

Premier Research

14 total trials

What the Registry Record Tells You About NCT02173808

The ClinicalTrials.gov registry entry for NCT02173808 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 627-participant average among 11 other Contraceptive Usage trials with a reported enrollment target (97% lower). The listed sponsor is Premier Research, which has 14 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Contraceptive Usage appearing as the primary indexed condition, and to 1 intervention - of which levonorgestrel butanoate is the first listed.

NCT02173808 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.

Frequently Asked Questions

What is clinical trial NCT02173808 about?

NCT02173808 is a clinical study titled "A Phase I Study to Evaluate the PK and PD of a Single Injection of Levonorgestrel Butanoate for Female Contraception". To evaluate the levonorgestrel (LNG) pharmacokinetic (PK) profile following injection of a single 20 mg dose of levonorgestrel butanoate (LB).

What is the current status of trial NCT02173808?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2011-05. Estimated completion is 2012-06.

What conditions does trial NCT02173808 study?

This clinical trial studies the following conditions: Contraceptive Usage.

What interventions are being tested in trial NCT02173808?

The interventions under investigation include: levonorgestrel butanoate (BIOLOGICAL).

Who is sponsoring clinical trial NCT02173808?

This trial is sponsored by Premier Research, which has 14 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02173808 being conducted?

This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Contraceptive Usage

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.